Werfen, a global developer, manufacturer and distributor of specialised diagnostic instruments, is to acquire Immucor, Inc, a US-based specialist in transfusion and transplant in vitro diagnostics, from private equity firm TPG for approximately $2 billion.
TPG acquired Immucor in July 2011 in a $1.97 billion deal, and has subsequently made multiple add-on acquisitions including Sentilus Inc and Organ-i Inc.
Upon completion of this acquisition, and based on 2021 figures, Werfen will surpass €2.2 billion in revenue, with seven technology centers, close to 7,000 employees worldwide, and a direct presence in 30 countries and more than 100 territories through distributors.
Read more: Private Equity Wire
